Search results
Showing 661 to 675 of 2044 results for guidelines
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guide describes the process NICE uses to develop NICE quality standards
NICE priority methodological research areas.
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.
An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing
Physical activity: brief advice for adults in primary care (PH44)
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (DG20)
Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Details about how accessible NICE services are and who to contact for alternative versions of information
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Vitamin D: supplement use in specific population groups (PH56)
This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.
children with fever, so the health economic impact of this and future guidelines can be estimated. Any explanatory notes(if applicable)